Page last updated: 2024-09-03

gefitinib and crizotinib

gefitinib has been researched along with crizotinib in 51 studies

Compound Research Comparison

Studies
(gefitinib)
Trials
(gefitinib)
Recent Studies (post-2010)
(gefitinib)
Studies
(crizotinib)
Trials
(crizotinib)
Recent Studies (post-2010) (crizotinib)
5,2315662,9191,7801121,718

Protein Interaction Comparison

ProteinTaxonomygefitinib (IC50)crizotinib (IC50)
Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2Homo sapiens (human)5.5
Tyrosine-protein kinase JAK2Homo sapiens (human)0.027
Sodium-dependent phosphate transport protein 2BHomo sapiens (human)0.051
Tyrosine-protein kinase ABL1Homo sapiens (human)0.5915
Tyrosine-protein kinase ABL1Mus musculus (house mouse)1.159
Epidermal growth factor receptorHomo sapiens (human)0.681
HLA class II histocompatibility antigen gamma chainHomo sapiens (human)0.0039
High affinity nerve growth factor receptorHomo sapiens (human)0.2905
Insulin receptorHomo sapiens (human)1.0966
Tyrosine-protein kinase LckHomo sapiens (human)1.8277
NucleophosminHomo sapiens (human)0.051
Insulin-like growth factor 1 receptorHomo sapiens (human)0.143
Hepatocyte growth factor receptorHomo sapiens (human)0.0057
Proto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)0.5458
Tyrosine-protein kinase JAK1Homo sapiens (human)0.563
Non-receptor tyrosine-protein kinase TYK2Homo sapiens (human)1.269
Tyrosine-protein kinase receptor UFOHomo sapiens (human)0.2223
Tyrosine-protein kinase JAK3Homo sapiens (human)1.36
ALK tyrosine kinase receptorMus musculus (house mouse)0.08
Angiopoietin-1 receptorHomo sapiens (human)0.2265
Angiopoietin-1 receptorMus musculus (house mouse)0.448
Macrophage-stimulating protein receptorHomo sapiens (human)0.25
BDNF/NT-3 growth factors receptorHomo sapiens (human)0.2005
Macrophage-stimulating protein receptorMus musculus (house mouse)0.08
Mitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)0.8745
Echinoderm microtubule-associated protein-like 4Homo sapiens (human)0.6542
ALK tyrosine kinase receptorHomo sapiens (human)0.4828

Research

Studies (51)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's39 (76.47)24.3611
2020's12 (23.53)2.80

Authors

AuthorsStudies
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Ai, J; Chen, Y; Geng, M; Jiang, H; Li, C; Liang, Z; Liu, H; Luo, C; Wang, Y; Zhai, Y; Zhang, D; Zhang, X; Zhao, F1
Bullock, AN; Canning, P; Choi, S; Cuny, GD; Mohedas, AH; Sanvitale, CE; Wang, Y; Xing, X; Yu, PB1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Ding, K; Lu, X; Smaill, JB1
Bharate, SB; Raghuvanshi, R1
Friedrich, MJ1
Moro-Sibilot, D1
Besse, B; Zalcman, G1
Giroux Leprieur, E; Planchard, D1
Shi, YK1
Besse, B; Chaubet-Houdu, M1
He, K; Yu, J; Zhang, L; Zheng, X1
Huber, RM; Reck, M; Thomas, M1
Couraud, S1
Bae, MK; Cho, BC; Haack, H; Hwang, SK; Jewell, SS; Kang, DR; Kim, HJ; Kim, HR; Kim, JH; Lim, SM; Ou, SH; Park, JK; Shim, HS; Shin, E; Soo, RA; Wang, J1
Aieta, M; Bulotta, A; Conteduca, V; Gregorc, V; Improta, G; Lazzari, C; Lerose, R; Tartarone, A; Zupa, A1
Chen, JJ; Chen, X; Ma, SN; Zhao, J; Zhou, JY1
Bria, E; Garassino, M; Massari, F; Pelosi, G; Peretti, U; Pilotto, S; Tortora, G1
Bellezza, G; Bennati, C; Chiari, R; Crinò, L; Duranti, S; Ludovini, V; Minotti, V; Pireddu, A1
Song, T; Wu, SX; Yu, W1
Axel, U; Baska, F; Greff, Z; Gyulavári, P; Ibolya, K; Kéri, G; Orfi, L; Peták, I; Szántai, KC; Szokol, B; Vantus, T; Zoltán, O1
Yano, S1
Eisenstein, M2
Cho, HJ; Chung, DH; Jeon, YK; Keam, B; Kim, DW; Kim, TM; Koh, J; Lee, DS; Lee, SH; Won, JK1
Garber, K1
Canoll, P; Chen, S; Guo, B; Horner, JW; Klingler, S; Paik, JH; Vaseva, AV; Wang, YA; Yan, H; Yao, J; Ying, H; Zhang, L; Zheng, H1
Azzoli, CG1
Nishio, K; Togashi, Y1
Watanabe, A1
Abe, T; Hirata, A; Ito, H; Mano, N; Sato, T; Yamaguchi, H1
Benveniste, MF; de Groot, PM; Papadimitrakopoulou, VA; Shroff, GS; Truong, MT; Viswanathan, C; Wu, CC1
Fukushima, T; Gomi, D; Katou, A; Kobayashi, T; Koizumi, T; Mamiya, K; Oguchi, K; Sekiguchi, N; Tateishi, K1
Chen, M; Tong, B; Wang, M; Xing, J; Xu, Y; Zhao, J; Zhong, W1
Goto, K; Hotta, K; Ichihara, E; Kato, Y; Kiura, K; Kubo, T; Kudo, K; Maeda, Y; Makimoto, G; Matsumoto, S; Ninomiya, K; Ninomiya, T; Ohashi, K; Sato, A; Tabata, M; Tomida, S; Toyooka, S; Umemura, S; Watanabe, H1
Li, W; Li, Y; Luo, W; Song, J; Tian, P; Zhang, R; Zhou, Y1
Li, H; Li, P; Liu, X; Ma, Z; Wang, H; Yan, X; Yang, J; Zhang, G; Zhang, M; Zhang, X; Zheng, X1
Han, B; Qiao, R; Wang, S; Xu, J; Zhang, B; Zhang, L; Zhang, Y; Zhao, Y1
Yang, N; Zeng, L; Zhang, Y; Zhou, C1
Dekker, H; Frampton, AE; Giovannetti, E; Honeywell, RJ; Kathmann, I; Keller, K; Liu, DSK; Musters, RJP; Pauwels, P; Peters, GJ; Porcelli, L; Rolfo, C; Ruijtenbeek, R; Van Der Steen, N; Van Meerloo, J1
Aberlenc, A; Bawa, O; Chauchereau, A; Farace, F; Faugeroux, V; Honore, A; Lacroix, L; Laplace-Builhe, C; Marty, V; Oulhen, M; Pawlikowska, P; Pommier, AL; Rouffiac, V; Scoazec, JY; Tayoun, T1
Fang, M; Gu, ZB; Huang, L; Liao, LM; Yao, GJ1
Fujita, A; Hatsuyama, T; Inotsume, N; Mukai, Y; Sato, H; Toda, T; Wakamoto, A; Yoshida, T1
Chen, Q; Gao, H; Gu, Y; Qin, S; Zeng, Q; Zhang, L1
Akrour, Y; Duchemann, B; Gaudry, S; Gibelin, A; Gonzalez, F; Jaubert, P; Moreau, AS; Oppenheimer, A; Stoclin, A; Tandjaoui-Lambiotte, Y1
Al-Hashami, Z; Ho, C; Leung, B; Moore, S; Pender, A; Shokoohi, A; Wang, Y; Wong, SK; Wu, J1
Li, W; Li, Y; Tian, P; Wang, K1
Lucia, F; Nicolas, E1

Reviews

12 review(s) available for gefitinib and crizotinib

ArticleYear
Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations.
    Journal of medicinal chemistry, 2020, 10-08, Volume: 63, Issue:19

    Topics: Chemistry, Pharmaceutical; Humans; Point Mutation; Protein Kinase Inhibitors

2020
[Brain metastases of non small cell lung cancers: systemic treatments].
    Bulletin du cancer, 2013, Jan-01, Volume: 100, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Crizotinib; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Pyrazoles; Pyridines; Quinazolines

2013
Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer.
    The European respiratory journal, 2013, Volume: 42, Issue:4

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemoradiotherapy; Clinical Trials as Topic; Combined Modality Therapy; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Gefitinib; Humans; Immunotherapy; Lung Neoplasms; Pyrazoles; Pyridines; Quinazolines

2013
Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.
    Lung cancer (Amsterdam, Netherlands), 2013, Volume: 81, Issue:3

    Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases

2013
Subsequent treatment choices for patients with acquired resistance to EGFR-TKIs in non-small cell lung cancer: restore after a drug holiday or switch to another EGFR-TKI?
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:1

    Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Drug Substitution; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Retreatment

2014
[Programs for continuing medical education: B session; 4. Progress in lung cancer therapy].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2014, Mar-10, Volume: 103, Issue:3

    Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cisplatin; Crizotinib; Drug Discovery; Education, Medical, Continuing; Erlotinib Hydrochloride; Etoposide; Gefitinib; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Small Cell Lung Carcinoma

2014
Practical Value of Molecular Pathology in Stage I-III Lung Cancer: Implications for the Clinical Surgeon.
    Annals of surgical oncology, 2015, Volume: 22, Issue:11

    Topics: Afatinib; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases

2015
[Kinase inhibitors and their resistance].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:8

    Topics: Antibodies, Monoclonal, Humanized; Benzamides; Biomarkers, Tumor; Crizotinib; Drug Discovery; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sorafenib; Sulfonamides; Trastuzumab; Vemurafenib

2015
[Companion Diagnostics for Solid Tumors].
    Rinsho byori. The Japanese journal of clinical pathology, 2015, Volume: 63, Issue:11

    Topics: Anaplastic Lymphoma Kinase; Biomarkers, Tumor; Breast Neoplasms; Cetuximab; Colonic Neoplasms; Crizotinib; Diagnostic Uses of Chemicals; Drug Discovery; ErbB Receptors; Gefitinib; Gene Fusion; Guidelines as Topic; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Molecular Targeted Therapy; Pharmacogenetics; Precision Medicine; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Trastuzumab

2015
Targeted Therapy and Imaging Findings.
    Journal of thoracic imaging, 2017, Volume: 32, Issue:5

    Topics: Angiogenesis Inhibitors; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Crizotinib; Diagnostic Imaging; Gefitinib; Humans; Lung; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines

2017
Combined Use of Crizotinib and Gefitinib in Advanced Lung Adenocarcinoma With Leptomeningeal Metastases Harboring MET Amplification After the Development of Gefitinib Resistance: A Case Report and Literature Review.
    Clinical lung cancer, 2019, Volume: 20, Issue:3

    Topics: Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Circulating Tumor DNA; Crizotinib; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Meningeal Neoplasms; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins c-met; Remission Induction

2019
[Radiation therapy and targeted therapies: Risks and opportunities].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2022, Volume: 26, Issue:6-7

    Topics: Ado-Trastuzumab Emtansine; Antineoplastic Agents; Cetuximab; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Mitogen-Activated Protein Kinase Kinases; Molecular Targeted Therapy; Panitumumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Radiotherapy; Receptor Protein-Tyrosine Kinases; Trastuzumab

2022

Trials

1 trial(s) available for gefitinib and crizotinib

ArticleYear
Correlation of early PET findings with tumor response to molecular targeted agents in patients with advanced driver-mutated non-small cell lung cancer.
    Medical oncology (Northwood, London, England), 2017, Sep-01, Volume: 34, Issue:10

    Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Treatment Outcome

2017

Other Studies

38 other study(ies) available for gefitinib and crizotinib

ArticleYear
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors.
    Bioorganic & medicinal chemistry, 2013, Nov-01, Volume: 21, Issue:21

    Topics: Animals; Antineoplastic Agents; Binding Sites; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dogs; Drug Resistance, Neoplasm; Half-Life; Humans; Madin Darby Canine Kidney Cells; Mice; Mice, Nude; Molecular Docking Simulation; Neoplasms; NIH 3T3 Cells; Phosphorylation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-met; Pyridines; Rats; Signal Transduction; Structure-Activity Relationship; Sulfonamides; Transplantation, Heterologous

2013
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
    Journal of medicinal chemistry, 2014, Oct-09, Volume: 57, Issue:19

    Topics: Activin Receptors, Type I; Aminopyridines; Humans; Mutation; Myositis Ossificans; Phenols; Protein Kinase Inhibitors; Structure-Activity Relationship

2014
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases

2022
NSCLC drug targets acquire new visibility.
    Journal of the National Cancer Institute, 2011, Mar-02, Volume: 103, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib; Tetrahydronaphthalenes; Treatment Outcome

2011
[What choice of first-line treatment?].
    Revue de pneumologie clinique, 2011, Volume: 67 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Evidence-Based Medicine; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Survival Analysis; Translocation, Genetic

2011
[What is the best sequence of treatment for patients with EGFR mutations?].
    Revue de pneumologie clinique, 2011, Volume: 67 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Evidence-Based Medicine; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome

2011
[Biomarkers and targeted therapies in non-small cell lung cancer: present and future treatments].
    Revue de pneumologie clinique, 2011, Volume: 67 Suppl 1

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Gefitinib; Gene Amplification; Genes, erbB-1; Humans; Lung Neoplasms; Medical Oncology; Mutation; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Treatment Outcome

2011
[Current status and perspectives of individualized therapy for non-small cell lung cancer based on molecular targeting].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:5

    Topics: Animals; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Crizotinib; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoglobulins, Intravenous; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Precision Medicine; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quality Control; Quinazolines

2012
Crizotinib induces PUMA-dependent apoptosis in colon cancer cells.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Colonic Neoplasms; Crizotinib; Drug Synergism; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrazoles; Pyridines; Quinazolines; Sorafenib; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2013
[About new treatments in thoracic oncology].
    Revue de pneumologie clinique, 2013, Volume: 69, Issue:2

    Topics: Afatinib; Antineoplastic Agents; Crizotinib; DNA Mutational Analysis; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Oncogene Proteins, Fusion; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines

2013
The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Anaplastic Lymphoma Kinase; Antigens, Differentiation, B-Lymphocyte; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Crizotinib; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Frequency; Gene Rearrangement; Glutamates; Guanine; Histocompatibility Antigens Class II; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridines; Pyrimidines; Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; Smoking; Treatment Outcome

2013
Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.
    Anti-cancer drugs, 2013, Volume: 24, Issue:10

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Crizotinib; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Mutation; Pyrazoles; Pyridines; Quinazolines; Xenograft Model Antitumor Assays

2013
Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013, Volume: 8, Issue:12

    Topics: Adenocarcinoma; Aged; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Crizotinib; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Salvage Therapy

2013
Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Mar-20, Volume: 32, Issue:9

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Crizotinib; Disease Progression; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Treatment Outcome

2014
[Development and biochemical characterization of EGFR/c-Met dual inhibitors].
    Acta pharmaceutica Hungarica, 2013, Volume: 83, Issue:4

    Topics: Afatinib; Aminopyridines; Anilides; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Computer Simulation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imidazoles; Lapatinib; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Pyridones; Quinazolines; Quinolines

2013
Clinical trials: More trials, fewer tribulations.
    Nature, 2014, May-29, Volume: 509, Issue:7502

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Crizotinib; DNA Mutational Analysis; Drug Approval; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Patient Selection; Proto-Oncogene Proteins B-raf; Pyrazoles; Pyridines; Quinazolines; Quinolines; Sample Size

2014
Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; DNA Mutational Analysis; Female; Gefitinib; Genes, erbB-1; High-Throughput Nucleotide Sequencing; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor Protein-Tyrosine Kinases; Sensitivity and Specificity; Sulfones; Translocation, Genetic

2015
Oncologists push beyond new lung cancer genomic testing guidelines.
    Journal of the National Cancer Institute, 2015, Volume: 107, Issue:2

    Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Testing; Genomics; Humans; Lung Neoplasms; Medical Oncology; Molecular Targeted Therapy; Mutation; Practice Guidelines as Topic; Precision Medicine; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Societies, Medical; Sulfones; Translocation, Genetic

2015
Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms.
    Cancer research, 2015, May-15, Volume: 75, Issue:10

    Topics: Animals; Brain Neoplasms; Crizotinib; Cyclin-Dependent Kinase Inhibitor p16; Doxycycline; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioma; Humans; Imidazoles; Mice, Inbred C57BL; Mice, Transgenic; Molecular Targeted Therapy; Phosphorylation; Protein Processing, Post-Translational; PTEN Phosphohydrolase; Pyrazoles; Pyridines; Quinazolines; Quinolines; Tumor Cells, Cultured

2015
Singapore Cancer Network (SCAN) Guidelines for the Use of Systemic Therapy in Advanced Non-Small Cell Lung Cancer.
    Annals of the Academy of Medicine, Singapore, 2015, Volume: 44, Issue:10

    Topics: Adenocarcinoma; Afatinib; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Crizotinib; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Maintenance Chemotherapy; Pemetrexed; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Singapore; Taxoids; Translocation, Genetic

2015
Interactions of crizotinib and gefitinib with organic anion-transporting polypeptides (OATP)1B1, OATP1B3 and OATP2B1: gefitinib shows contradictory interaction with OATP1B3.
    Xenobiotica; the fate of foreign compounds in biological systems, 2018, Volume: 48, Issue:1

    Topics: Crizotinib; Drug Interactions; Gefitinib; HEK293 Cells; Humans; Liver; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines

2018
Prognostic role of circulating tumor cells in patients with EGFR-mutated or ALK-rearranged non-small cell lung cancer.
    Thoracic cancer, 2018, Volume: 9, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Count; Crizotinib; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Rearrangement; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplastic Cells, Circulating; Prognosis; Quinazolines

2018
Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
    Cancer science, 2018, Volume: 109, Issue:10

    Topics: Anilides; Animals; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Heparin-binding EGF-like Growth Factor; Histocompatibility Antigens Class II; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Sodium-Phosphate Cotransporter Proteins, Type IIb; Up-Regulation; Xenograft Model Antitumor Assays

2018
Mutation tracking of a patient with EGFR-mutant lung cancer harboring de novo MET amplification: Successful treatment with gefitinib and crizotinib.
    Lung cancer (Amsterdam, Netherlands), 2019, Volume: 129

    Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors

2019
Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
    Targeted oncology, 2019, Volume: 14, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Gene Rearrangement; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Retrospective Studies; Survival Rate; Young Adult

2019
Responder of Gefitinib Plus Crizotinib in Osimertinib Failure EGFR-mutant NSCLC-Resistant With Newly Identified STRN-ALK by Next-Generation Sequencing.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2019, Volume: 14, Issue:7

    Topics: Acrylamides; Adult; Anaplastic Lymphoma Kinase; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Calmodulin-Binding Proteins; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Membrane Proteins; Mutation; Nerve Tissue Proteins; Prognosis

2019
Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function.
    Journal of cellular physiology, 2020, Volume: 235, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lysosomes; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met

2020
Exploitation of the chick embryo chorioallantoic membrane (CAM) as a platform for anti-metastatic drug testing.
    Scientific reports, 2020, 10-09, Volume: 10, Issue:1

    Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Chick Embryo; Chorioallantoic Membrane; Cisplatin; Crizotinib; Docetaxel; Drug Screening Assays, Antitumor; Gefitinib; Male; Neoplasm Metastasis; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms

2020
New lung-cancer drugs extend survival times.
    Nature, 2020, Volume: 587, Issue:7834

    Topics: Acrylamides; Afatinib; Aminopyridines; Anaplastic Lymphoma Kinase; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; B7-H1 Antigen; Carbazoles; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Gefitinib; Hope; Humans; Lactams; Lung; Lung Neoplasms; Piperidines; Programmed Cell Death 1 Receptor; Pyrazoles; Quinazolinones; Survival Analysis

2020
Patient with EGFR-mutant lung cancer harboring de novo MET amplification successfully treated with gefitinib combined with crizotinib.
    Current problems in cancer, 2021, Volume: 45, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Crizotinib; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Proto-Oncogene Proteins c-met; Treatment Outcome

2021
An Liquid Chromatography-Tandem Mass Spectrometry Method for the Simultaneous Determination of Afatinib, Alectinib, Ceritinib, Crizotinib, Dacomitinib, Erlotinib, Gefitinib, and Osimertinib in Human Serum.
    Therapeutic drug monitoring, 2021, 12-01, Volume: 43, Issue:6

    Topics: Acrylamides; Afatinib; Aniline Compounds; Carbazoles; Chromatography, Liquid; Crizotinib; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Quinazolinones; Sulfones; Tandem Mass Spectrometry

2021
Coexistence of a secondary STRN-ALK, EML4-ALK double-fusion variant in a lung adenocarcinoma patient with EGFR mutation: a case report.
    Anti-cancer drugs, 2021, 09-01, Volume: 32, Issue:8

    Topics: Acrylamides; Adult; Anaplastic Lymphoma Kinase; Aniline Compounds; Calmodulin-Binding Proteins; Cell Cycle Proteins; Crizotinib; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Membrane Proteins; Microtubule-Associated Proteins; Nerve Tissue Proteins; Protein Kinase Inhibitors; Serine Endopeptidases

2021
Tyrosine Kinase Inhibitors for Acute Respiratory Failure Because of Non-small-Cell Lung Cancer Involvement in the ICU.
    Chest, 2022, Volume: 161, Issue:1

    Topics: Acrylamides; Adenocarcinoma of Lung; Adult; Aged; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Intensive Care Units; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Noninvasive Ventilation; Oxygen Inhalation Therapy; Protein Kinase Inhibitors; Respiration, Artificial; Respiratory Insufficiency; Retrospective Studies; Survival Rate

2022
Effect of targeted therapy and immunotherapy on advanced nonsmall-cell lung cancer outcomes in the real world.
    Cancer medicine, 2022, Volume: 11, Issue:1

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; DNA Mutational Analysis; Female; Gefitinib; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Nivolumab; Retrospective Studies; Survival Analysis

2022
Acquired MET-DSTN Fusion Mediated Resistance to EGFR-TKIs in Lung Adenocarcinoma and Responded to Crizotinib Plus Gefitinib: A Case Report.
    Clinical lung cancer, 2022, Volume: 23, Issue:1

    Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Crizotinib; Destrin; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Oncogene Proteins, Fusion; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met

2022